This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Uncategorised Disease
  • /
  • Reductions in Systolic Blood Pressure with Liraglu...
Journal

Reductions in Systolic Blood Pressure with Liraglutide in Patients with Type 2 Diabetes: Insights from a Patient–Level Pooled Analysis of Six Randomized Clinical Trials

Read time: 1 mins
Published:25th Mar 2020

Aims:

To quantify the effect of liraglutide on systolic blood pressure (SBP) and pulse in patients with type 2 diabetes (T2D), and assess the influence of covariates on observed SBP reductions.

Methods:

A patient–level pooled analysis of six phase 3, randomized trials was conducted.

Results:

The analysis included 2792 randomized patients. In the intention–to–treat population (n=2783), mean [±SE] SBP reductions from baseline with liraglutide 1.2mg (2.7 [0.8] mmHg) and 1.8mg (2.9 [0.7] mmHg) once daily were significantly greater than with placebo (0.5 [0.9] mmHg; P=0.0029 and P=0.0004, respectively) after 26 weeks, and were evident after 2 weeks. Liraglutide was also associated with significantly greater SBP reductions than glimepiride and, at a dose of 1.8mg, insulin glargine and rosiglitazone. SBP reductions with liraglutide weakly correlated with weight loss (Pearson�s correlation coefficient: 0.08–0.12; P≤0.0148). No dependence of these reductions on concomitant antihypertensive medications was detected (P=0.1304). Liraglutide 1.2 and 1.8mg were associated with mean increases in pulse of 3 beats per minute (bpm), versus a 1bpm increase with placebo (P<0.0001 for each dose versus placebo).>

Conclusions:

Liraglutide reduces SBP in patients with T2D, including those receiving concomitant antihypertensive medication.

Read abstract on library site